Kestra Medical Technologies, founded in 2014 and headquartered in Kirkland, Washington, specializes in wearable medical devices and digital healthcare solutions aimed at protecting patients at risk of sudden cardiac arrest (SCA). Their flagship product, the ASSURE® system, integrates continuous monitoring, autonomous arrhythmia detection, and defibrillation therapy to provide comprehensive cardiac protection. The system includes the Kestra CareStation™ remote patient data platform and the ASSURE patient application, facilitating seamless communication between patients and healthcare providers. In July 2024, Kestra secured $196 million in an oversubscribed Series B funding round to expand its commercial operations and advance its mission of safeguarding at-risk patients. As of January 2025, the ASSURE system is actively prescribed by over 550 hospitals across the United States and has been utilized by more than 17,000 patients since its full commercial launch. Additionally, Kestra is preparing for an initial public offering (IPO) in the first half of 2025, signaling a significant milestone in its growth trajectory. (February 2025)